Atrial septal defect percutaneous closure
|
Atrial Septal Defect Microchapters | |
|
Treatment | |
|---|---|
|
Surgery | |
|
| |
|
Special Scenarios | |
|
Case Studies | |
|
Atrial septal defect percutaneous closure On the Web | |
|
American Roentgen Ray Society Images of Atrial septal defect percutaneous closure | |
|
Risk calculators and risk factors for Atrial septal defect percutaneous closure | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Priyamvada Singh, MBBS [[2]]; Cafer Zorkun, M.D., Ph.D. [3]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [[4]]
Overview
Percutaneous transcatheter closure is used in limited atrial septal defect cases. The Food and Drug Administration has only authorized the use of percutaneous closure in ostium secundum patients.
Mechanisms of benefit
The Ampltazer septal occluder (ASO) is the most commonly used device as it allows closure of large cavities, is easy to implant, and boasts high success rates. As an instrument, the ASO consists of two self-expandable round discs connected to each other with a 4-mm waist, made up of 0.004–0.005´´ nitinol wire mesh filled with Dacron fabric. Implantation of the device is relatively easy. The prevalence of residual defect is low. It occludes the opening and benefits by preventing the shunting of blood across the lesion.
Indication
Percutaneous transcatheter closure is currently only indicated for the closure of ostium secundum atrial septal defects. In patients with a secundum defect, there must be a sufficient rim of tissue around the septal defect.
Contra-indications
It should not be used in patients with sinus venosus, primum or patent foramen ovale atrial septal defects.
Types of occluders
The Food and Drug Administration has authorized the following percutaenous transcatheters for usage:[1]
- Amplatzer septal occluder
- CardioSEAL
- HELEX septal occluder
- Sideris patch
Pre-surgical considerations
Prior to undergoing percutaneous closure, eligible atrial septal defect patients must undergo pharmacologic preparation therapy. Most therapy regimens include antiplatelet drugs to protect patients against thrombus formation. Prior to percutaneous closure, ostium secundum atrial septal defect patients undergo antiplatelet therapy such as aspirin or clopidogrel for a minimum of six months. This antiplatelet therapy protects patients against thrombus formation.
Secundum defects are assessed via echocardiographic monitoring to determine the anatomic viability of percutaneous closure. The ideal secundum defect is less than 30mm in diameter with an accompanying rim of tissue around the defect of at least 5mm. This rim of tissue serves to prevent impingement upon the superior vena cava (SVC), inferior vena cava (IVC), as well as the tricuspid or mitral valves.[2]
Benefits
Complications
Supportive trial data
In a study done on 236 patients with secundum atrial septal defects (ASD), to evaluate the safety and efficacy of transcatheter closure with the amplatzer septal occlude, the device was found to be very efficient. It causes atrial septal defect closure in 84.7% of the treated patient population. During a median follow up of 2.3 years complete closure was documented in 94%, with a residual shunt only in 12 patients. Two of the treated patients were reported to have procedure related complications like retroperitoneal bleeding and air embolism.[3]
<youtube v=Gros-u7YCTk/>
<youtube v=4c3CEgjj2PY/>
References
- ↑ Schwetz BA (2002). "From the Food and Drug Administration". JAMA. 287 (5): 578. PMID 11829678.
- ↑ Ferreira SM, Ho SY, Anderson RH (1992). "Morphological study of defects of the atrial septum within the oval fossa: implications for transcatheter closure of left-to-right shunt". Br Heart J. 67 (4): 316–20. PMC 1024841. PMID 1389707.
- ↑ Fischer G, Stieh J, Uebing A, Hoffmann U, Morf G, Kramer HH (2003). "Experience with transcatheter closure of secundum atrial septal defects using the Amplatzer septal occluder: a single centre study in 236 consecutive patients". Heart. 89 (2): 199–204. PMC 1767528. PMID 12527678.